Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deferiprone: New insight.

A Piga1, S Roggero, T Vinciguerra

  • 1Department of Pediatric Hematology/Oncology, University of Turin, Turin, Italy. antonio.piga@unito.it

Annals of the New York Academy of Sciences
|December 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biventricular and bia-trial strain by cardiac magnetic resonance in thalassaemia intermedia: patterns and correlates.

Clinical radiology·2025
Same author

Age determination, growth and otolith shape analysis of Lepidotrigla cavillone from Sardinian and Sicilian waters (Mediterranean Sea).

Journal of fish biology·2025
Same author

Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Shark immune system: A review about their immunoglobulin repertoire.

Fish & shellfish immunology·2025
Same author

Sampson and Cookson's commentary: What is it good for?

Health policy (Amsterdam, Netherlands)·2024
Same author

Ex vivo biomechanical evaluation of 2.4 mm LCP plate rod constructs versus 2.7 mm LCP applied to the feline tibia.

Veterinary surgery : VS·2023
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
Same journal

Synchrony and Reciprocity in Rhythmic Interaction.

Annals of the New York Academy of Sciences·2026
See all related articles

Deferiprone shows greater cardioprotection than deferoxamine, improving heart health in iron overload patients. Combining chelators may speed up iron reduction and reverse heart disease, but requires further study.

Area of Science:

  • Hematology
  • Cardiology
  • Pharmacology

Background:

  • Iron overload is a significant concern in various medical conditions.
  • Deferoxamine and deferiprone are key iron chelators used in treatment.
  • Cardiotoxicity is a major complication of iron overload.

Purpose of the Study:

  • To compare the cardioprotective effects of deferiprone versus deferoxamine.
  • To evaluate the efficacy of combined chelation therapy in iron overload.
  • To assess the impact of chelation on myocardial health and iron excretion.

Main Methods:

  • Retrospective analysis of patient data.
  • Review of myocardial magnetic resonance imaging (MRI) findings.
  • Observation of treatment outcomes in patients receiving single or combined chelation therapy.

Related Experiment Videos

Main Results:

  • Deferiprone demonstrates superior cardioprotection compared to deferoxamine.
  • Patients on long-term deferiprone show improved myocardial MRI patterns.
  • Combination therapy with deferiprone and deferoxamine appears to enhance iron excretion and accelerate cardiac recovery.

Conclusions:

  • Deferiprone is emerging as a preferred oral iron chelator for improving cardiac outcomes.
  • Combined chelation therapy shows promise for faster mitigation of iron overload and reversal of heart disease.
  • Further randomized controlled trials are necessary to confirm these findings and optimize treatment strategies.